Abstract
As oral anticoagulation reduces thromboembolic stroke risk in patients with atrial fibrillation, it is important that patients continue therapy. With the introduction of novel oral anticoagulants (NOACs) in Europe, clinicians and payers are interested in real-world data comparing persistence between
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
